Digestive Disease Week® 2025 took place from May 3 through May 6 in San Diego, California. Sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, and The Society for Surgery of the Alimentary Tract, Digestive Disease Week® is a major event for professionals in gastroenterology and related fields. 

Digestive Disease Week® 2025 featured over 13,000 attendees, 4,300 research presentations, and 400 expert-led sessions. The following is a brief sampling of some of the posters presented at Digestive Disease Week® 2025.

Risk of Bleeding After Esophageal and Gastric Endoscopic Mucosal Resection in Patients with Cirrhosis: A U.S. Multicenter Propensity-Matched Study

  • Details: In clinical practice, for gastric and esophageal lesions endoscopic mucosal resection (EMR) is frequently used, but the safety profile of the procedure in cirrhosis patients is incomplete.
  • Result: The study found that cirrhosis does not notably increase the risk of adverse outcomes after gastric and esophageal EMR. The study’s findings support the safety of EMR in appropriately selected patients.

Does Depth of Submucosal Invasion in Esophageal Adenocarcinoma Actually Increase the Risk of Lymph Node Metastasis?

  • Details: Recent questioning positioned the relationship of depth of submucosal invasion being a risk factor for lymph node metastasis in doubt. The study evaluated the relationship between the depth of submucosal invasion of esophageal adenocarcinoma with lymph node metastasis.
  • Result: The limited scope of the study should be taken into consideration, and larger studies will be needed to confirm, but no difference was noted in lymph node metastasis and tumor depth of submucosal invasion.

Endoscopic Vacuum Therapy For the Management of Upper Gastrointestinal Tract Leaks and Defects: A Retrospective Study from a Tertiary Referral Center in Nearly 100 Patients

  • Details: Endoscopic Vacuum Therapy (EVT) is a promising tool for managing leaks and defects in the UGI tract. This study examined the efficacy of EVT.
  • Result: The study found EVT is an effective and safe treatment for UGI defects.

TRAF3IP2: A Putative Oncogene in Colorectal Cancer

  • Details: TRAF3-Interacting Protein 2 (TRAF3IP2) is an adaptor protein that may modulate colorectal cancer development and progression.
  • Result: The study demonstrated, for the first time, a notable association between colorectal cancer and TRAF3IP2, identified as a putative oncogene in colon cancer.

Progressive Loss of Myosin 5B in Inflammatory Bowel Disease and Colorectal Cancer
Details: Myosin 5b is a motor protein that is crucial for the maintenance of epithelial homeostasis and for intracellular trafficking. Evidence suggests disruption to epithelial integrity and cellular trafficking may lead to IBD and colorectal cancer. The study sought to further examine the expression of Myosin 5b in IBD, IBD-associated colorectal cancer, and non-IBD-associated colorectal cancer.
Result: Restoring Myosin 5b expression in patients may improve colorectal cancer outcomes. Myosin 5b was seen as beneficial to maintaining colonic homeostasis and the pathogenesis of IBD and cancer.

For a complete overview of posters presented at Digestive Disease Week® 2025, visit the official site.

Sign up for alerts and stay informed on the latest published guidelines and stay tuned for more conference recaps.

Copyright © 2025 Guideline Central, all rights reserved.